Curium Acquires Nucleis to Strengthen PET Radiopharmaceutical Capabilities

• Curium has acquired Nucleis, a Belgian PET radiopharmaceutical manufacturer and CDMO.

• The acquisition expands Curium’s production capacity and strengthens its PET diagnostics capabilities in Europe.

Curium, a global company in nuclear medicine, has completed the acquisition of Nucleis, a GMP manufacturer and distributor of PET radiopharmaceutical drugs based in Belgium.

The transaction supports Curium’s strategy to strengthen its position in the PET imaging market and enhance access to F-18 tracers across Europe. Nucleis, established in 2017 as a spin-off from the University of Liège, serves the Benelux region and also offers contract manufacturing services to other nuclear medicine developers.

According to Curium, the acquisition adds essential manufacturing capacity and supports the development and supply of radiopharmaceuticals used in oncology, neurology, and cardiology diagnostics. Curium also plans to integrate its proprietary tracers into the Nucleis product portfolio.

Benoit Woessmer, CEO of Curium EU, stated: “This acquisition is an additional step in expanding our PET footprint and enhancing our capabilities in the European nuclear medicine market.”

Fabrice Giacomelli, former CEO of Nucleis, commented that the company’s integration into Curium opens a new phase of growth. He noted that Nucleis will benefit from Curium’s infrastructure and expertise, enabling faster development and delivery of advanced PET tracers for both patients and healthcare providers.